Sun Yat-sen University: all 1,680 studies

Page 1 of 17. Open to participants first (609), then studies with results posted, then the rest; newest registration first within each.

• Becotatug Vedotin + Pucotenlimab+Platinum Induction and Sequential CCRT for Unresectable LA NSCLCNot yet recruitingNCT07882940Phase 2
• Remimazolam vs Propofol for Long-Term Sedation in Mechanically Ventilated ICU PatientsNot yet recruitingNCT07880548Phase 3
• Phase II Trial of Hypofractionated Radiotherapy Guided by Optical Surface Imaging and Fan-beam CT for Thymoma With Pleural MetastasisNot yet recruitingNCT07879417Phase 2
• Prospective Phase II Study of Concurrent Radiotherapy Combined With Full-Course Immunotherapy or Consolidation Immunotherapy for Locally Advanced NSCLCNot yet recruitingNCT07874464Phase 2
• HR20013 for the Prevention of Nausea and Vomiting in Patients With Cancer: A Real-World StudyRecruitingNCT07874308
• Lenvatinib Plus Bevacizumab and PD-1 Inhibition Versus Bevacizumab Plus PD-1 Inhibition After Progression on Bevacizumab Plus Sintilimab in Unresectable Hepatocellular Carcinoma: A Prospective, Randomized, Two-Cohort, Phase II StudyNot yet recruitingNCT07870772Phase 2
• A Phase II Study of Anlotinib + PD-1 Inhibitor vs. PD-1 Inhibitor Maintenance After First-Line Chemoimmunotherapy in Advanced ESCC (Esophageal Squamous Cell Carcinoma)RecruitingNCT07863141Phase 2
• Cryoablation Combined With Hepatic Arterial Infusion of Iparomlimab and Tuvonralimab (QL1706), Intravenous Dacarbazine, and Oral Lenvatinib in Patients With Liver Metastases From Malignant Melanoma: a Single-arm, Phase II, Prospective TrialRecruitingNCT07847359Phase 2
• Multi-Theory Model-Based AI Agent Intervention for Smoking Cessation in Early-Stage Cancer PatientsNot yet recruitingNCT07827066Not applicable
• Local Ablation Plus Systemic Therapy for Metachronous Liver and/or Lung Oligometastases From Nasopharyngeal CarcinomaNot yet recruitingNCT07824856Phase 2
• Ivosidenib Plus mFOLFOXIRI and Celecoxib for BRAF-targeted Therapy-refractory BRAF V600E-mutant Colorectal Cancer PatientsRecruitingNCT07809893Phase 2
• Prophylactic Nanocrystalline Megestrol Acetate Versus Placebo for Chemoradiotherapy-Related Anorexia in Nasopharyngeal CarcinomaRecruitingNCT07796789Phase 3
• Effects of Different PICC Catheterization Methods: A Multicenter Randomized Controlled TrialNot yet recruitingNCT07791719Not applicable
• VIPeerAgent for Adolescent Mental HealthNot yet recruitingNCT07778758Not applicable
• Trastuzumab Rezetecan and Carboplatin ± Bevacizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-sensitive Recurrent Ovarian CancerNot yet recruitingNCT07776171Phase 2
• Research on Colorectal Cancer Recurrence Monitoring and Individualized Treatment Based on MRDRecruitingNCT07775950Not applicable
• Radiotherapy Combined With Capeox Chemotherapy, Sintilimab and Suvemcitug in Locally Advanced pMMR Rectal Cancer:a Prospective Clinical TrialNot yet recruitingNCT07774754Phase 2
• Neoadjuvant Pucotenlimab and Becotatug Vedotin for Locally Advanced Penile CancerNot yet recruitingNCT07767266Phase 2
• Neoadjuvant Presurgical Becotatug Vedotin (MRG003) Plus Pucotenlimab (HX008) in Oral Cavity Squamous Cell CarcinomaNot yet recruitingNCT07766889Phase 2
• Radscopal Radiotherapy Plus Immunotherapy for Chemotherapy-Ineligible Patients With Newly Diagnosed Metastatic Nasopharyngeal Cancer: A Single-Center, Open-Label, Phase II StudyNot yet recruitingNCT07756190Phase 2
• Golidocitinib Plus Anthracycline-based Therapy for Untreated Nodal T-follicular Helper (TFH) Cell LymphomaNot yet recruitingNCT07753642Phase 2
• Neoadjuvant Chemoradiotherapy Combined With CTLA-4 Monoclonal Antibody Plus PD-1 Monoclonal Antibody for Locally Advanced Esophageal CancerRecruitingNCT07751055Phase 2
• Tunlametinib in Combination With Pucotenlimab and Hydroxychloroquine in NRAS Mutant MelanomaRecruitingNCT07750067Phase 2
• Culmerciclib Plus Anlotinib and Endocrine Therapy for HR-Positive/HER2-Negative Metastatic Breast Cancer With Brain MetastasesNot yet recruitingNCT07745257Phase 2
• Culmerciclib in HR+/HER2+ Advanced Breast CancerRecruitingNCT07732491Phase 2
• FOLFIRI Plus Bevacizuamb and QL1706 in Second-Line Treatment for mCRCNot yet recruitingNCT07729605Phase 3
• Dapagliflozin Add-on in Unresectable HCC With Metabolic SyndromeNot yet recruitingNCT07729592Phase 2
• Efficacy and Safety of Tunlametinib Combination Therapy in the Treatment of Second-line and Above Metastatic Colorectal CancerNot yet recruitingNCT07714447Phase 2
• An Umbrella-designed Prospective Multicenter Randomized Open-label Superiority Trial Evaluating Multi-biomarker-guided Precision Therapy for First-line Treatment of Advanced Esophageal Squamous Cell CarcinomaNot yet recruitingNCT07709533Phase 2
• Efficacy and Safety of TPC Induction Chemotherapy Combined With Nimotuzumab and Toripalimab "Immune Sandwich" Regimen Versus Full-Course Immunotherapy for Locally Advanced Nasopharyngeal CarcinomaRecruitingNCT07706985Phase 3
• Efficacy and Safety of Becotatug Vedotin (MRG003) Combined With Anti-PD1 as Maintenance Therapy for Recurrent and Metastatic Nasopharyngeal CarcinomaRecruitingNCT07705243Phase 3
• Sacituzumab Tirumotecan (Sac-TMT/SKB264) Plus Tagitanlimab (KL-A167) in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction AdenocarcinomaNot yet recruitingNCT07701681Phase 2
• Management Strategy of 1L Lorlatinib With Hyperlipidemia in Stage IIIB-IV ALK Positive NSCLCNot yet recruitingNCT07674524
• Individualized Primary Clinical Target Volume Based on Margin Expansion for Nasopharyngeal CarcinomaRecruitingNCT07661771Phase 3
• Rituximab Maintenance Versus Observation After R2 Induction in Previously Untreated Marginal Zone LymphomaNot yet recruitingNCT07654465Phase 2
• Transanal Total Mesorectal Excision vs Robotic Total Mesorectal ExcisionRecruitingNCT07651553Not applicable
• Study on the Effects and Mechanisms of Probiotic Supplementation in Ameliorating Uric Acid Metabolism in Asymptomatic Hyperuricemic IndividualsNot yet recruitingNCT07650214Not applicable
• Tumor Neoantigen Vaccine SarVac Combined With Tumor Specific Lymphocyte Reinfusion in the Treatment of Advanced SarcomaRecruitingNCT07648069Phase 1
• Iparomlimab and Tuvonralimab Plus Paclitaxel and Platinum as Neoadjuvant Therapy for Locally Advanced Cervical CancerRecruitingNCT07646301Phase 2
• Neoadjuvant Docetaxel, Cisplatin, and Dual Immunotherapy for Sinonasal CarcinomaNot yet recruitingNCT07645846Phase 2
• Thymosin Alpha 1 Combined With Anti-PD-1 Monoclonal Antibody in Elderly Patients With Advanced MelanomaRecruitingNCT07644897Phase 2
• Adebrelimab Combined With Neoadjuvant Chemotherapy in Borderline Resectable Locally Advanced Esophageal Squamous Cell CarcinomaRecruitingNCT07638436Phase 2
• QL1706 Plus Anlotinib as a Later-line Treatment for Patients With Advanced Lung CancerNot yet recruitingNCT07636226Phase 2/3
• New Triple Combination Therapy in Newly Diagnosed Type 2 DiabetesNot yet recruitingNCT07635953Phase 3
• Trastuzumab Rezetecan(SHR-A1811) Combined With Ivonescimab (AK112) in Locally Advanced or Metastatic Non-small Cell Lung Cancer Harboring HER2 Gene AbnormalitiesNot yet recruitingNCT07630077Phase 2
• Pirtobrutinib Maintenance After CAR-T Therapy in Relapsed or Refractory B-Cell LymphomaNot yet recruitingNCT07622784Phase 2
• Neoadjuvant Radiotherapy Combined With NALIRIFOX and Adebrelimab in pMMR/MSS Locally Advanced Rectal Cancer: A Prospective, Randomized, Phase II Clinical TrialRecruitingNCT07622771Phase 2
• FOLFOX8 Versus mFOLFOX6 With Bevacizumab or Cetuximab for First-Line Unresectable Metastatic Colorectal Cancer (Phase II)Not yet recruitingNCT07621497Phase 2
• BRIDGE Study: Neoadjuvant Finotonlimab, Cetuximab, and Docetaxel in Resectable Recurrent HNSCC After Immunotherapy ProgressionEnrolling by invitationNCT07618624Phase 2
• Adebrelimab Combined With SHR2554 in Relapsed/Refractory PTCL and NK/T-Cell LymphomaNot yet recruitingNCT07615283Phase 1/2
• Dalpiciclib, Anti-HER2 Therapy, and Endocrine Therapy for Hormone-Receptor-Positive, HER2-Positive Metastatic Breast CancerRecruitingNCT07610720Phase 2
• AI-Assisted Optimization of Online Adaptive Radiotherapy for Gastric LymphomaNot yet recruitingNCT07609355Not applicable
• Hypofractionated Chemoradiotherapy With Tislelizumab and Surufatinib for Unresectable Stage III NSCLCRecruitingNCT07609121Phase 2
• Sintilimab Plus Chemotherapy as Induction Therapy for Unresectable Stage IIIC NSCLCNot yet recruitingNCT07603661Phase 2
• A Descriptive Study of the Correlation Between Postpartum Depression and Body Image Dissatisfaction, Self-objectification, and Social Media Appearance ComparisonNot yet recruitingNCT07603063
• Cryoablation Plus Camrelizumab for Advanced Soft Tissue SarcomaRecruitingNCT07602049Phase 2
• Lisaftoclax Plus Chidamide and Rituximab in Relapsed or Refractory Diffuse Large B-cell LymphomaNot yet recruitingNCT07601607Phase 1/2
• Teprotumumab N01 Versus Methylprednisolone After Urgent Orbital Decompression for Dysthyroid Optic NeuropathyNot yet recruitingNCT07594912Phase 2
• Effects of Different Tunnel Methods in PICC CatheterizationRecruitingNCT07594704Not applicable
• Becotatug Vedotin Combined With Pucotenlimab as Neoadjuvant Therapy for Resectable Recurrent Head and Neck Squamous Cell Carcinoma After Progression on Immunotherapy: A Prospective Phase II StudyNot yet recruitingNCT07589049Phase 2
• Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid TumorsRecruitingNCT07584499Phase 1
• Teniposide, Cisplatin and Serplulimab for Treatment of ES-SCLC, a Randomized Controlled StudyRecruitingNCT07583511Phase 2
• Prospective, Single Arm, Observational Study of Faricimab in the Treatment of Neovascular Age-related Macular Degeneration (nAMD)Not yet recruitingNCT07581782
• Intrathecal Morphine for Quality of Recovery After Open Abdominal Surgery Within an Enhanced Recovery PathwayNot yet recruitingNCT07575321Not applicable
• A Phase II Study of Sintilimab, Pegaspargase and Selinexor Followed by Radiotherapy in Newly Diagnosed Stage I/II Extranodal NK/T-Cell LymphomaNot yet recruitingNCT07574528Phase 2
• The Experience of Short Video Addiction Among College StudentsNot yet recruitingNCT07574021
• Taurine for the Prevention and Treatment of Radiation-induced Oral Mucositis in Patients With Nasopharyngeal CarcinomaNot yet recruitingNCT07567742Phase 2
• Becotatug Vedotin Plus PD-1 Monoclonal Antibody and Radiotherapy for Unresectable Locally Recurrent Nasopharyngeal CarcinomaNot yet recruitingNCT07555860Phase 2
• Full-wrap Versus Conventional Suspension for Reducing Soft Palate Injury Rate in Transoral SurgeryNot yet recruitingNCT07552545Not applicable
• Phosphate-Containing Replacement Fluid for Patients Undergoing CRRTNot yet recruitingNCT07550894Phase 3
• Goniotomy in Primary Congenital GlaucomaNot yet recruitingNCT07550868
• Sonrotoclax, Zanubrutinib and Rituximab in Previously Untreated Patients With Follicular LymphomaNot yet recruitingNCT07550855Phase 2
• Neoadjuvant Iparomlimab/Tuvonralimab Plus CAPEOX Versus Iparomlimab/Tuvonralimab Plus CAPEOX and Propranolol for Locally Advanced pMMR Colon Cancer: A Prospective, Single-Center, Multi-Cohort StudyNot yet recruitingNCT07549906Phase 2
• Megestrol Acetate for Fatigue Management in T-DXd Treated Breast CancerRecruitingNCT07543536Phase 3
• Nudging for Anticoagulation Adherence in Atrial FibrillationNot yet recruitingNCT07543393Not applicable
• Sintilimab, Chidamide, and Azacitidine for Untreated Stage I-II Extranodal NK/T-Cell LymphomaNot yet recruitingNCT07542912Not applicable
• GAPP Induction and Concurrent Chemoradiotherapy for High-risk Locoregionally Advanced NPC.Not yet recruitingNCT07540390Phase 3
• Effects and Mechanisms of Dietary Carbohydrate Intake and Quality on Glucose and Lipid MetabolismNot yet recruitingNCT07533513Not applicable
• Phase II Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Albumin-Bound Paclitaxel and Lenvatinib as Second-Line Therapy for Unresectable or Metastatic Biliary Tract CancerRecruitingNCT07530445Phase 2
• Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal CancerRecruitingNCT07528209Phase 3
• Maintenance Immunotherapy With Deferred Salvage Radiotherapy After Response to Chemoimmunotherapy in Recurrent Nasopharyngeal CarcinomaRecruitingNCT07528183Phase 2
• Becotatug Vedotin (MRG003) With PD-1 Blockade and Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal CarcinomaNot yet recruitingNCT07524413Phase 3
• A Short-Bout Combined Aerobic and Resistance Exercise Program in Older Adults With Diabetes and Probable SarcopeniaNot yet recruitingNCT07522359Not applicable
• Evaluation of an Undisturbed Embryo Culture System for Embryo Development in IVF/ICSI CyclesNot yet recruitingNCT07522281Not applicable
• A Multicenter, Single-Arm, Phase II Exploratory Study of Eribulin in Combination With Anlotinib for HER2-Negative Recurrent/Metastatic Breast Cancer Previously Treated With Antibody-Drug ConjugatesRecruitingNCT07520760Phase 2
• Efficacy and Safety of Chidamide+Sintilimab+Bev as Second-Line Therapy in Advanced Extrapulmonary Neuroendocrine CarcinomaRecruitingNCT07518602Phase 2
• Serial ctDNA and Molecular Residual Disease Monitoring in NeuroblastomaRecruitingNCT07516678
• The Association Between Gut Microbiome Composition Signature and Cancer-related Symptoms in Children With Acute Lymphoblastic LeukemiaEnrolling by invitationNCT07515430
• Intraoperative Rectal Lavage to Prevent Local Recurrence After Laparoscopic Mid-to-Low Rectal Cancer Resection: A Multicenter Randomized TrialRecruitingNCT07512232Not applicable
• A Study of Disitamab Vedotin, Tunlametinib, and PD-1 Antibody for Advanced Gastric CancerNot yet recruitingNCT07507526Phase 2
• Efficacy and Safety Comparison Between Intensified Therapy and Conversion Therapy For Advanced HCC After Failure of First-lineRecruitingNCT07501351Phase 2
• Ischemic Preconditioning Reduces the Severity of Acute Kidney Injury After Partial NephrectomyNot yet recruitingNCT07497958Not applicable
• Becotatug Vedotin for LA-NPC With a Suboptimal Response to Induction Chemotherapy Combined With ImmunotherapyRecruitingNCT07496190Phase 2
• Celecoxib Plus R-CHOP vs R-CHOP in Newly Diagnosed Advanced CD5+ DLBCLRecruitingNCT07494565Phase 2
• SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLCNot yet recruitingNCT07489703Phase 2
• Safety and Efficacy of Yiwoxidan Anti (AK112) Monotherapy in Patients With Metastatic Renal Clear Cell Carcinoma Who Are Intolerant to TKI Treatment: a Prospective, Single Arm, Phase II Clinical StudyEnrolling by invitationNCT07488572Phase 2
• TACE or Ablation Combined With Sintilimab and Ipilimumab N01 as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With Intermediate-High Recurrence RiskNot yet recruitingNCT07487662Phase 2
• Bevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain MetastasesRecruitingNCT07481786Phase 3
• Causation And Prognosis Analyses of Coronary Artery Diseases: A Longitudinal Cohort StudyRecruitingNCT07480512
• Radiotherapy After Prostatectomy for Node Positive Prostate CancerRecruitingNCT07477626Phase 3

← Sun Yat-sen University overview and focus areas